Daewoong Shows Three Drug Delivery Platforms
Daewoong Pharmaceutical presented its CURE, CLOPAM and Thermicra drug delivery technologies at an international conference in Boston.
Updated on Nov. 2, 2026 in Diabetes
Daewoong Pharmaceutical introduced three platform technologies at PODD 2026, an international drug delivery conference held in Boston from October 29 to 30, 2026. The company presented CURE, CLOPAM and Thermicra, each aimed at improving how drugs are administered.
Why it matters
The platforms target long-acting, skin-patch and high-concentration delivery, which could make injectable and needle-based treatments more practical for patients. Daewoong's plans to partner on external candidate materials signal a broader push to license its delivery technology.
The presentations included pharmacokinetic studies of CURE with peptide drugs and absorption and blood-concentration results for CLOPAM with GLP-1 class drugs used for obesity and diabetes. Clinical outcomes and approval timelines for these platforms were not disclosed.
The players
Daewoong Pharmaceutical
A South Korean drug company whose platform technologies were the focus of its presentations at the Boston conference.
Kim Kwan-young
Head of Daewoong Pharmaceutical's Formulation Technology Center who delivered an oral presentation at the event.
The details
CURE uses biodegradable polymer microparticles to release drugs continuously over a set period, while CLOPAM delivers drugs through tiny needles in a skin patch. Thermicra reduces the volume of biopharmaceuticals so antibodies and antibody-drug conjugates can be given subcutaneously; Kim Kwan-young, head of the company's Formulation Technology Center, gave an oral presentation on the first day.
Timeline
October 29-30, 2026: PODD 2026 conference held in Boston
November 2, 2026: Daewoong announced its participation in PODD 2026
Diabetes Context
CLOPAM's data on GLP-1 class drugs connects to the wider effort to offer weekly or less frequent treatments for obesity and diabetes that reduce daily injections. The microneedle patch approach extends that effort to a skin-based format rather than a needle injection.
If these platforms reach the market, patients using GLP-1 drugs could eventually have options beyond daily or weekly self-injection. Any change in how these medicines are given would depend on future clinical results and regulatory approval.
The takeaway
New delivery formats for diabetes and obesity drugs are being developed to reduce injection burden, but the platforms shown at this conference remain in development without disclosed clinical timelines. Readers should watch for trial results and regulatory filings before expecting changes in treatment.
Further reading
For related coverage of treatment approaches, see the Diabetes section.
Source note: This article includes information reported by Business Korea.
